ALT001 drug trial for MSA-C cerebellar subtype
Summary
The National Library of Medicine registered a new clinical trial on ClinicalTrials.gov for ALT001, an investigational drug for the cerebellar subtype of Multiple System Atrophy (MSA-C). The trial is categorized as an interventional study. ClinicalTrials.gov is a publicly accessible database operated by the NIH as required under FDA regulations for clinical trial registration and results reporting.
What changed
A new clinical trial registration (NCT07514923) for ALT001 targeting the cerebellar subtype of Multiple System Atrophy (MSA-C) was added to the ClinicalTrials.gov registry. The entry includes standard required fields: study title, intervention type, trial phase classification, enrollment information, locations, and contact details for investigators. Clinical trials are required to be registered on ClinicalTrials.gov under FDAAA 801 and FDA regulations.
For sponsors and investigators conducting MSA-C research, this registration signals active enrollment activity for an investigational therapy. Healthcare providers treating MSA-C patients may want to be aware of this trial for patient referral considerations. The registration is mandatory under US law for applicable clinical trials and contributes to transparency in drug development.
What to do next
- Monitor ClinicalTrials.gov for trial updates and results
- Review eligibility criteria when enrolling patients in MSA-C research studies
Source document (simplified)
Show glossary
Related changes
Get daily alerts for ClinicalTrials.gov
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov publishes new changes.